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Background: Clinicians, providers and guideline panels use absolute effects to weigh the advantages and
downsides of treatment alternatives. Relative measures have the potential to mislead readers. However, little is
known about the reporting of absolute measures in systematic reviews. The objectives of our study are to
determine the proportion of systematic reviews that report absolute measures of effect for the most important
outcomes, and ascertain how they are analyzed, reported and interpreted.
Methods/design: We will conduct a methodological survey of systematic reviews published in 2010. We will
conduct a 1:1 stratified random sampling of Cochrane vs. non-Cochrane systematic reviews. We will calculate the
proportion of systematic reviews reporting at least one absolute estimate of effect for the most patient-important
outcome for the comparison of interest. We will conduct multivariable logistic regression analyses with the report-
ing of an absolute estimate of effect as the dependent variable and pre-specified study characteristics as the inde-
pendent variables. For systematic reviews reporting an absolute estimate of effect, we will document the methods
used for the analysis, reporting and interpretation of the absolute estimate.
Discussion: Our methodological survey will inform current practices regarding reporting of absolute estimates in
systematic reviews. Our findings may influence recommendations on reporting, conduct and interpretation of
absolute estimates. Our results are likely to be of interest to systematic review authors, funding agencies, clinicians,
guideline developers and journal editors.
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When contemplating a recommendation, either in favour
of or against an intervention, guideline developers need to
consider the balance between desirable and undesirable
consequences of treatment alternatives [1]. Also, clinicians
and patients seeking shared decision-making need to
understand the magnitude of benefits and harms.
Measures of effect of an intervention on dichotomous
outcomes may express a change in risk in relative terms
(that is, risk ratio, also known as relative risk and relative
risk reduction (RRR)), in absolute terms (that is, absolute
risk reduction (ARR), also known as risk difference), or
as the inverse of the risk difference (that is, the number
needed to treat (NNT)) [2].
The impact of an intervention may appear small or
large depending on which measure of effect is reported,
an issue that is referred to as statistical framing [2,3].
Clinicians are more inclined to prescribe a drug that re-
duces the relative risk of death by 50% than one that re-
duces the absolute risk of death from 2% to 1%, or that
requires 100 patients to be treated to prevent a single pre-
mature death [4,5]. This finding is in spite of the fact that
these three presentations (RRR, ARR and NNT, respect-
ively) express the same effect. Similarly, patients are more
willing to start a lipid-lowering drug when benefit is pre-
sented as a RRR versus an ARR [6].
Empirical evidence suggests that relative effect mea-
sures are, on average, more consistent than absolute
measures [7,8]. Indeed, studies in patients with differing
severities of disease, or studies with different lengths of
follow-up, will almost certainly have varying risk differ-
ences due to varying baseline risks. For this reason, it is
wise to avoid performing meta-analyses directly on risk
differences, unless there is a clear reason to suspect that
risk differences will be consistent in a particular clinical
situation [9,10].
To report one or more absolute effects in accompani-
ment to relative effects, systematic review authors should
apply the measure of relative effect to a baseline risk or
control group risk. This involves expressing the absolute
difference for each clinically identifiable risk group, and
clarifying the time period to which this applies. Conse-
quently, a relative risk is expressed as a variety of risk dif-
ferences or NNTs across a range of control risks in
subpopulations that clinicians can easily identify [8,9,11].
GRADE [11,12], which represents an emerging consensus
for rating the quality of the evidence, suggests that when
summarizing the evidence, together with the best estimate
of relative effects, authors present the best estimates of
absolute risks in intervention and control groups and
the difference in the two risks, with the corresponding
confidence intervals that convey the precision of esti-
mates. Estimates of absolute risk should be provided in
this manner consistently for both benefits and harms orburdens. The Cochrane Collaboration provides similar
guidance [13].
An analysis of the top general medical journals showed
that 68% of randomized controlled trials (RCTs) and co-
horts failed to report absolute risks in the abstract. Of
these articles, about half did report the underlying abso-
lute risks elsewhere in the article (text, table or figure)
but half did not report them anywhere [14]. More re-
cently, a study found that research articles published in
top journals in the field of health inequalities reported
both relative and absolute effects only 7% of the time in
the full text and 2% in the abstract [15].
In the case of systematic reviews in three leading
medical journals (Lancet, JAMA and BMJ) Sedrakyan and
Shih [16] reported that authors fail to include absolute
estimates. Additionally, in a research letter, Beller et al. [17]
reported that only 4% of systematic reviews include both
absolute and relative estimates of effect in the abstract.
These analyses have come from a relatively limited sample
of journals and only explored the reporting of estimates.
Given the lack of information about this topic and the
potential implications for decision-making in healthcare
[18], it is important to explore how this issue is managed in
published systematic reviews.
The objectives of this study are to evaluate the propor-
tion of systematic reviews that report absolute measures
of effect for the most important outcome, and ascertain
how are they calculated, reported and interpreted. Add-
itionally, the study will evaluate the frequency of mis-
matched framing, that is, the use of relative measures




We will conduct a methodological survey of Cochrane
and non-Cochrane systematic reviews. We will use
standard methodology for conducting systematic reviews
[13], as described in previous protocols from our group
[19-22]. We did not register the project in the PROS-
PERO database.
Definitions
The risk of an outcome in a group is the proportion of
individuals in that group who suffer that outcome. Mea-
sures of effect (whether relative or absolute) express the
risk of an outcome in one group compared with another.
As relative measures of effect, the relative risk is the ra-
tio of the risk of an outcome, whereas the odds ratio
(OR) is the ratio of the odds of an outcome [8]. As an
absolute measure of effect, the risk difference is the dif-
ference between the observed risk in the experimental
and control groups. It can also be expressed as the arith-
metic difference between two outcome rates. The NNT,
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risk difference, which translates into the number of sub-
jects who need to be treated to prevent one additional
outcome, good (NNT) or bad (number needed to harm).
Cochrane systematic reviews are defined as all system-
atic reviews published in the Cochrane Database of Sys-
tematic Reviews. All the other systematic reviews will be
considered non-Cochrane systematic reviews.
Eligibility criteria
We will include systematic reviews published in English
meeting the following criteria:
1. Described as a ‘systematic review’ or a ‘meta-analysis’;
2. Reports a search strategy in at least one database;
3. Published in 2010; in the Cochrane Database of
Systematic Reviews or indexed in MEDLINE;
4. Includes a comparison of an intervention with
another intervention or no intervention in human
beings;
5. Reports measures of effect for at least one
dichotomous outcome either from a single study or
from a pooled analysis.
If there is more than one pairwise comparison, reviewers
will select the comparison that reports the largest number
of dichotomous outcomes. If more than one comparison
reported the same number of dichotomous outcomes, re-
viewers will select the comparison that reports the largest
number of absolute estimates. We will identify the most
patient-important outcome using a hierarchical approach
(Appendix 1). If the outcome is a composite outcome, we
will select the most patient-important of those included in
the composite, if authors provide disaggregated data in
the review (according to the hierarchy in Appendix 1).
Otherwise, we will choose the next most important di-
chotomous outcome. Since we are interested in how au-
thors present the results of their systematic reviews (for
example, results obtained when combining the included
studies), we will not collect information about absolute
effects presented when describing individual studies in-
cluded in the review, unless the comparison of interest
includes only one trial.
Search strategy
We will use the MEDLINE database to search for poten-
tially eligible systematic reviews. We will use two distinct
search strategies. First, we will use an adaptation of the
systematic review filter, designed by the Health Informa-
tion Research Unit of McMaster University to retrieve
non-Cochrane systematic reviews. Second, we will use
the Ovid ‘search by journal’ filter to identify Cochrane
systematic reviews (Appendix 2). We will limit both
searches to the year 2010. We will subsequently exportcitations to Endnote X4.0.2., and then into a web-based
systematic review software (DistillerSR, Evidence Partners,
Ottawa, Canada; https://systematic-review.ca) for eligibil-
ity screening and data extraction.
Random sampling of citations
All identified citations will be stratified into Cochrane
and non-Cochrane search results. We will obtain a ran-
dom sample within each stratum and screen it accord-
ing to our eligibility criteria. We will repeat the random
sampling process as needed until reaching the final sample
size, which will include the same number of Cochrane
and non-Cochrane systematic reviews (see sample size
section).
Review process
We will undertake, in a duplicate and independent man-
ner, title and abstract screening, full text screening and
data abstraction. Irrespective of discrepancies, all studies
selected at a title and abstract level will be included for
the full text screening. Reviewers will resolve discrepan-
cies at the level of full text and data abstraction by con-
sensus, and if unsuccessful, with the help of a third
reviewer. This arbitrator will independently review the
article before discussing it with the reviewers. To ensure
the validity and consistency of the process, we will con-
duct calibration exercises for each step of the process.
We will also develop and pilot-test standardized forms
and upload them onto the online systematic review soft-
ware application. We will accompany all forms with de-
tailed instructions. A core group will meet regularly to
discuss progress and potential difficulties. We will create
a study flow to describe the results of the different steps
of the selection process.
Data extraction
We will extract the following information from each in-
cluded systematic review: study characteristics, quality of
the systematic review, the calculation and reporting of
absolute estimates of effects, and the interpretation of
absolute estimates of effects.
Study characteristics
For all included systematic reviews, we will extract the
following information:
1. Type of systematic review (Cochrane vs. not
Cochrane);
2. Type of intervention (pharmacologic vs. other);
3. High-impact (Journal of the Medical Association,
New England Journal of Medicine, Lancet, Annals of
Internal Medicine, Journal of the American Medical
Association and PLoS Medicine) vs. other journals;
4. Quality of the review;
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6. Statistical significance of the effect for the most
patient-important outcome;
7. Source of funding (partially or completely funded by
private for-profit organization or authors with finan-
cial conflicts of interest vs. others).
Specifically, we will collect information about whether
the review was published in the five journals with the
most journal citations (Journal of the American Medical
Association, New England Journal of Medicine, Annals
of Internal Medicine, Lancet and PLoS Medicine), the
population and the intervention and control of interest.
We will also extract information about source of funding
(partially or completely funded by private for-profit
organization vs. others) and the type of intervention
(pharmacologic vs. other). We will note whether the
systematic review used the GRADE approach; this in-
cludes whether authors provide a summary table, such
as a summary of findings.
We will note whether the reviews include an absolute
measure of effect (for example, ARR, NNT) for the most
patient-important outcome for the selected comparison.
We will also note this for any outcome other than the most
patient-important, for both the comparison of interest and,
if available, any other comparison. For the selected com-
parison, we will note whether the authors report benefits
and harm outcomes and whether they report a measure of
relative effect, a measure of absolute effect or both.
Quality of the systematic reviews
We will assess the methodological quality of eligible sys-
tematic reviews using the AMSTAR instrument [23].
Calculation and reporting of absolute estimate of effects
For those reviews that report at least one absolute effect
estimate, we will record whether these estimates relate
to the most patient-important outcome, any outcome
within the comparison of interest or elsewhere in the full
text. For the reviews that provide an absolute estimate
for the most patient-important outcome, we will collect
information about the type of measure (for example, risk
difference, NNT) and the expression used when report-
ing if available (for example, risk reduced by 5%). We
will explore how authors calculated the absolute esti-
mates (for example, direct calculation from a meta-
analysis); or modelled from baseline risk (for example,
the median baseline risk from the included studies) and
whether they state the calculation methods in their
methods section. We will document the number of esti-
mates of effect for different baseline risks and, if available,
whether authors specify the source of these baseline esti-
mates. If needed, we will contact authors for additional
information.Interpretation of absolute estimates of effects
Regarding interpretation, we will document whether au-
thors discuss the fact that risk differences may vary to
an important degree across subpopulations. We will also
document the extent to which authors discuss this poten-
tial variability and their interpretation of the main effect of
interest. Finally, we will assess whether the absolute esti-
mates of effects are considered in the conclusion (a separ-
ate conclusion section or in the conclusion of a discussion
section).
Sample size
We will calculate the sample size on the basis of an exam-
ination of study characteristics associated with the report-
ing of absolute effects for the most patient-important
outcome: we will undertake this by means of a regression
analysis. In this model we will include seven study charac-
teristics with a total of eight categories of variable. We will
require ten events per category to examine the association.
Previous estimates show that approximately 50% of sys-
tematic reviews report an absolute estimate of effect [16].
We will consider 40% as our best estimate when consider-
ing the most patient-important outcome. Therefore, we
will probably require a sample size of approximately 200
systematic reviews for our study. To increase our confi-
dence in our sample size estimate, we will conduct a pilot
study of 60 systematic reviews to further inform the final
sample size.
Analysis
We will assess agreement between reviewers’ judgements
of whether the investigators reported an absolute measure
of effect for the most patient-important outcome. We will
calculate chance-corrected agreement and interpret the
results according to Landis and Koch guidelines (κ values
of 0 to 0.20 represent slight agreement, 0.21 to 0.40 fair
agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80
substantial agreement, and greater than 0.80 almost per-
fect agreement) [24].
We will calculate the proportion of systematic reviews,
reporting at least one absolute estimate of effect for the
most patient-important outcome, for any outcome within
the comparison of interest, or for any comparison and any
dichotomous outcome excluding the comparison of inter-
est. We will conduct two multivariable logistic regression
analyses to examine the association between pre-specified
study characteristics and, first, the reporting of an absolute
estimate of effect for the most patient-important outcome
and, second, the reporting of an absolute estimate of effect
for any outcome within the comparison of interest.
We will also calculate the proportion of systematic re-
views that report the method they used to calculate the
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systematic reviews that discuss whether risk differences
may vary across populations anywhere in the article. We
will conduct two separate multivariable logistic regression
analyses to examine the association with the pre-specified
study characteristics and respectively these two features of
risk difference calculation and interpretation.
In addition, we will calculate the proportion of system-
atic reviews that use, for the comparison of interest, rela-
tive measures for benefit outcomes and absolute measures
for harm (‘mismatched framing’ henceforth). Treating the
reporting of results with mismatched framing as the
dependent variable, we will conduct multivariable logistic
regression analyses to examine its association with the
pre-specified study characteristics.
Our pre-specified study characteristics for the regres-
sion analyses are listed and ranked by importance. If
there are sufficient events, we will include them all.
Otherwise, we will include as many as possible according
to our ten events-per-category rule (see section on sam-
ple size). The first two factors to be examined will be
type of systematic review (Cochrane vs. not Cochrane)
and use of GRADE. However if, as we will explain, there
is excessive confounding, we will not include GRADE in
the regression:
We hypothesize that systematic reviews are more likely
to report absolute effects or report them appropriately if
they: (i) are Cochrane reviews, (ii) use GRADE, (iii) are of
better quality, (iv) achieve statistical significance for the
most patient-important outcome, (v) do not receive fund-
ing from for-profit organizations or their authors have fi-
nancial conflicts of interest, (vi) evaluate pharmacological
interventions, (vii) are published in a high-impact journal
(Journal of American Medical Association, New England
Journal of Medicine, The Lancet, British Medical Journal,
Annals of Internal Medicine and Public Library of Science
Medicine).
Before the regressions, we will look at the proportion
of Cochrane and not-Cochrane systematic reviews that
include a GRADE approach. We suspect that GRADE
might be reported seldom in non-Cochrane systematic
reviews and relatively frequently in Cochrane systematic
reviews. If this is the case, there will be excessive con-
founding between use of GRADE and Cochrane reviews
and it will be inappropriate to include them in the same
regression.
If this proves to be the case, we will use the following
analytical approach. We will compare Cochrane system-
atic reviews with and without GRADE. If there is a signifi-
cant difference, we will then compare Cochrane with
GRADE vs. non-Cochrane and Cochrane without GRADE
vs. non-Cochrane. The results of these analyses will deter-
mine whether we include Cochrane or GRADE or both in
the complete regression.Discussion
Main objectives of our study
Our review will establish the proportion of systematic
reviews reporting absolute measures of effect and how
Cochrane and non-Cochrane systematic reviews calcu-
late, report and interpret these measures. We will evalu-
ate the frequency in systematic reviews of mismatched
framing, characterized by the use of relative measures
for efficacy outcome and absolute measures for harm
outcomes. Given the lack of information about this topic
and the potential implications for decision-making in
healthcare [18], we believe it is important to explore
how this issue is managed in published systematic re-
views. By publishing this protocol we are reflecting our
commitment to making the objectives and design of
methodological studies more transparent [19-22].
Strengths and limitations
Our study has several strengths. First, we will use trans-
parent and rigorous methods, including explicit eligibility
criteria, sensitive search strategies and the use of standard-
ized forms. We will pilot these forms and develop detailed
instructions for both study screening and data extraction,
and achieve near perfect agreement between reviewers be-
fore commencing study selection and data extraction. We
will evaluate each of the reviews and extract data in dupli-
cate and independently. Second, we will include both
Cochrane and non-Cochrane systematic reviews and use,
as opposed to previous studies, broad inclusion criteria to
make our results more generalizable. Third, as in our pre-
vious projects [21], we will conduct a pilot study to im-
prove the accuracy of our final sample size calculation.
Fourth, we will explore issues that have not previously
been addressed, including the type of absolute estimate re-
ported and the method used for calculation. Finally, the
feasibility of our study is increased due to the experience
of our group in completing methodological studies involv-
ing large samples [25-27].
Our study has potential limitations. First, it will in-
volve several reviewers’ judgements at each step of the
process. The detailed instructions, piloting and calibra-
tion exercises described previously should help to
minimize disagreement. Second, some of the reviewers
are less experienced than others. To overcome this limi-
tation, we will partner less experienced reviewers with
those who are more experienced. We will also have a
steering group that will meet regularly to discuss pro-
gress and potential difficulties.
Previous research
Several studies have addressed the use of absolute effects in
leading medical journals. Two of them explored this issue
in individual studies observing that absolute estimates
are very often not reported, especially in the abstract
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centage was strikingly low (9%) [15]. To our knowledge,
only two studies have explored this issue in the context of
systematic reviews. One study explored this issue in three
of the top medical journals (The Lancet, JAMA and BMJ)
showing that approximately 50% of the reviews included
frequency data and one-third mismatched framing of
benefit and harms [16]. This analysis was from a relatively
limited sample of journals and the analysis did not explore
the issue beyond the actual reporting of these estimates.
Beller et al. have explored this issue but only in the ab-
stract of systematic reviews [17].
While there is agreement that both patients and health
professionals understand absolute estimates better than
relative estimates, there is inconclusive evidence about
the optimal way, in terms of understanding, for report-
ing absolute estimates. Some studies suggest that natural
frequencies are preferable and others favour percentages
[3,28,29]. Previous evaluations of absolute estimate re-
porting, regardless of the included designs, have not pro-
vided either detailed information about what type of
absolute estimates are most often used in systematic re-
views or what methods authors use to calculate these.
To the extent that systematic reviews include the latter,
their results are more likely to be well understood and,
hence, optimally implemented.Implications
The findings of ARROW will inform the systematic review
community about the current practice of absolute esti-
mates reporting in both Cochrane and non-Cochrane
reviews. Our findings may influence recommendations
on reporting, conduct and interpretation of absolute es-
timates in this type of research design. Our results are
likely to be of great interest for systematic review au-
thors and developers, funding agencies, health decision
makers, guideline developers, and journal editors.Appendix 1 Outcome importance hierarchy
I. Mortality;
a. All causes of mortality;
b. Disease-specific mortality.
II. Morbidity
a. Cardiovascular major morbid outcomes;
b. Other major morbid outcomes (for example, loss
of vision, seizures, fracture, revascularization);
c. Recurrence, relapse, remission of cancer,
disease-free survival;
d. Renal failure requiring dialysis;
e. Hospitalizations;
f. Infections;
g. Dermatological or rheumatologic disorders.III. Symptoms, quality of life, or functional status (for
example, failure to become pregnant, successful
breastfeeding, depression);
IV. Surrogate outcomes (for example, diagnosis of
tuberculosis, viral load, physical activity, weight loss,
post-operative atrial fibrillation, cognitive function).
Categories I, II, or III but not category IV define a
patient-important outcome. For a composite endpoint
to be patient-important all its components have to be
patient-important.
Appendix 2 Search strategy
Ovid MEDLINE search strategy for no Cochrane
systematic reviews.




5. (systematic adj (review$1 or overview$1)).tw.
6. exp "Review Literature as Topic"/
7. 3 or 4 or 5 or 6
8. cochrane.ab.
9. embase.ab.
10. (psychlit or psyclit).ab.
11. (psychinfo or psycinfo).ab.
12. (cinahl or cinhal).ab.
13. science citation index.ab.
14. bids.ab.
15. cancerlit.ab.






22. 17 or 18 or 19 or 20 or 21
23. selection criteria.ab.
24. data extraction.ab.
25. 23 or 24
26. Review/






33. 31 not (31 and 32)
34. or/28-30,33
35. 7 or 16 or 22 or 27
36. 35 not 34
37. 36 not "cochrane database of systematic reviews".jn.
38. limit 37 to yr = "2010"
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1. "cochrane database of systematic reviews".jn.
2. limit 1 to yr = "2010"
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